Exelixis, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Morrissey
- Full Time Employees
- 1,147
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1851 Harbor Bay Parkway Alameda CA United States of America 94502
- IPO Date
- Apr 17, 2000
- CIK
- 0000939767
- Website
- exelixis.com
- Similar Companies
- Business
- Exelixis, Inc. (Nasdaq: EXEL) is an oncology-focused biotechnology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers. The company offers CABOMETYX (cabozantinib) tablets for advanced renal cell carcinoma, hepatocellular carcinoma, and previously treated advanced neuroendocrine tumors; COMETRIQ (cabozantinib) capsules for metastatic medullary thyroid cancer; and COTELLIC (cobimetinib), partnered with Roche/Genentech for advanced melanoma. Exelixis advances a diversified pipeline of small-molecule therapeutics and biotherapeutics, including bispecific antibodies, antibody-drug conjugates, next-generation kinase inhibitors such as zanzalintinib in phase 3 trials for renal cell carcinoma, hepatocellular carcinoma, and squamous cell carcinoma of the head and neck, and early-stage programs like XL309 targeting PARP inhibitors. Founded in 1994 and headquartered in Alameda, California, the company conducts global operations through strategic partnerships with Bristol Myers Squibb, Merck, Takeda Pharmaceutical, and others to expand development and commercialization reach. Recent developments include U.S. FDA approval of a new CABOMETYX indication for previously treated advanced neuroendocrine tumors; authorization of a $500 million stock repurchase program in February 2025 following completion of a prior $500 million program from August 2024, with over $1.2 billion returned to shareholders since March 2023; plans to initiate phase 3 trials for zanzalintinib in neuroendocrine tumors and two Merck-collaborated renal cell carcinoma studies in 2025; and ongoing enrollment in XL309 monotherapy and combination trials for PARP-refractory tumors.
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket
Exelixis, Inc. (EXEL) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative
Exelixis: Financial Performance Improves Faster Than Market Expectations
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
Exelixis, Inc. (EXEL) Presents at Stifel 2026 Targeted Oncology Virtual Forum Transcript
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis, Inc. (EXEL) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
Prediction: This Stock Could Double By 2031
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy?
Exelixis, Inc. (EXEL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May